New drug BI 3000202 tested in Liver-Impaired patients

NCT ID NCT07486102

Recruiting now Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study is recruiting 44 adults aged 18 to 80, including both healthy people and those with liver problems. All participants will take a single tablet of the drug BI 3000202. Researchers will measure how the drug moves through the body and check for side effects over about one month. The goal is to see if liver problems change how the drug is processed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 3000202
What this could lead to: If successful, this study could help doctors understand how to dose BI 3000202 safely for patients with liver problems.
What could go wrong: This is a very early phase 1 study with only 44 participants. It is designed to gather data, not to test if the drug works for any disease. The drug may not be effective or safe in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY HEPATIC IMPAIRMENT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

American Research Corporation at the Texas Liver Institute
RECRUITING

San Antonio, Texas, 78215, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.